









Markets
/
Stocks
/
nasdaq-enov
/

Enovis Corp

ENOV

22.590USD

+0.800+3.67%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

1.29BMarket Cap

LossP/E TTM



Enovis Corp

22.590

+0.800+3.67%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Enovis Corp

Currency: USD Updated: 2026-02-06

Key Insights

Enovis Corp's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 41 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 45.45.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Enovis Corp's Score

Industry at a Glance

Industry Ranking

41 / 205

Overall Ranking

131 / 4521

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Enovis Corp Highlights

StrengthsRisks

Enovis Corporation is a medical technology company. It is focused on developing clinically differentiated solutions by manufacturing and distributing high-quality medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. It operates through two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment provides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative diseases. The Prevention & Recovery products are marketed under several brand names, such as DJO. The Reconstructive segment provides surgical implant solutions, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools. It also operates a Enovis Growth eXcellence business system (EGX).

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 34.84% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 2.11B.

Overvalued

The company’s latest PE is -0.93, at a high 3-year percentile range.

Held by Invesco

Star Investor Invesco holds 200.74K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.36.

Analyst Rating

Based on 12 analysts

Buy

Current Rating

45.455

Target Price

+99.27%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Enovis Corp is 6.97, ranking 115 out of 205 in the Healthcare Equipment & Supplies industry. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 548.91M, representing a year-over-year increase of 8.65%, while its net profit experienced a year-over-year increase of 1711.95%.

Score

Industry at a Glance

Previous score

6.97

Change



Financials

6.81

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.71

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

7.59

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.54

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.19

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Enovis Corp's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Enovis Corp is 8.24, ranking 35 out of 205 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -0.93, which is -5.00% below the recent high of -0.88 and -28809.00% above the recent low of -268.13.

Score

Industry at a Glance

Previous score

8.24

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 41/205

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Enovis Corp is 8.50, ranking 24 out of 205 in the Healthcare Equipment & Supplies industry. The average price target is 49.00, with a high of 58.00 and a low of 33.00.

Score

Industry at a Glance

Previous score

8.50

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 12 analysts

Buy

Current Rating

45.455

Target Price

+99.27%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

114

Total

Median

Average

Company name

Ratings

Analysts

Enovis Corp

ENOV

Stryker Corp

SYK

Abbott Laboratories

ABT

Medtronic PLC

MDT

Dexcom Inc

DXCM

Zimmer Biomet Holdings Inc

ZBH

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Enovis Corp is 6.64, ranking 110 out of 205 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 27.99 and the support level at 19.10, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.49

Change

0.15

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.133

Neutral

RSI(14)

42.217

Neutral

STOCH(KDJ)(9,3,3)

54.519

Buy

ATR(14)

1.128

High Vlolatility

CCI(14)

-24.024

Neutral

Williams %R

54.040

Neutral

TRIX(12,20)

-0.846

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

22.230

Buy

MA10

22.206

Buy

MA20

23.459

Sell

MA50

26.001

Sell

MA100

28.444

Sell

MA200

29.979

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Enovis Corp is 10.00, ranking 1 out of 205 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 125.63%, representing a quarter-over-quarter decrease of 2.05%. The largest institutional shareholder is The Vanguard, holding a total of 6.40M shares, representing 11.19% of shares outstanding, with 5.13% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

7.96M

-0.70%

The Vanguard Group, Inc.

Star Investors

6.49M

+1.90%

American Century Investment Management, Inc.

4.73M

-0.13%

Dimensional Fund Advisors, L.P.

2.97M

+1.75%

Rubric Capital Management LP

2.75M

Davenport Asset Management

2.81M

+1.85%

Dorsey Asset Management LLC

2.40M

-6.03%

State Street Investment Management (US)

2.35M

-5.57%

Hood River Capital Management LLC

1.73M

-0.42%

River Road Asset Management, LLC

1.44M

+0.07%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Enovis Corp is 6.05, ranking 65 out of 205 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.26. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.